Primary sarcoma of the heart is a rare disease that has an ominous prognosis with either medical or surgical therapy. We report a case of a 25-year-old woman with sarcoma of the heart who received a transplant and is clinically well after 7 years. We believe that transplantation must be considered in this kind of pathology for selected cases.
Our patient was a 25-year-old woman who was diagnosed with Hodgkin lymphoma at age 16 years. She was treated with chemotherapy and mediastinal radiotherapy and experienced total remission. As sequela, she had some degree of lung fibrosis and hypothyroidism.
In August 2001, the patient was unexpectedly admitted to the hospital with complaints and signs of right-sided heart failure. An echocardiogram showed a tumor mass filling the right ventricular cavity, and a computed tomography scan and cardiac magnetic resonance imaging confirmed those findings and excluded any other locations. Without other diagnosis and given her severe New York Heart Association functional class IV condition, she underwent an open heart operation.
A biopsy specimen was obtained from the tumor mass inside the right ventricle, and the pathology report identified sarcoma. Considering the ominous result, partial debulking of the tumor was done, trying to maintain the cavity-filling function of the ventricle without putting the patient at risk with a too-aggressive resection, namely at the septal area where we could create a ventricular septal defect.
The patient's postoperative period was without complications. She was referred for chemotherapy and underwent a perfusion of ifosfamide (1500 mg/m 2 ) for 3 days. One month later, she was readmitted with gross rightsided heart failure, and the echocardiogram showed extensive recurrence of the tumor mass, with protrusion of the tumor through the tricuspid valve into the right atrium (Fig 1) . At this point, there seemed to be no other medical or surgical options owing to the type of the recurrent tumor involving the heart. Computed tomography scans and liver and bone perfusion scans were able to exclude any metastasis or invasion at distant locations, and cardiac transplantation came as a last option.
The patient underwent cardiac transplantation in December 2001 that was performed with a biatrial technique. The tumor invaded the ventricular wall, the papillar muscles, and the cords of the tricuspid valve, but not the anulus, the right atrium, or the epicardium. This was confirmed by the microscopic examination.
She experienced no major events in the postoperative period. The patient is receiving routine triple-drug immunosuppression with azathioprine (25 mg daily), cyclosporine (75 mg twice daily), and prednisolone (7.5 mg daily). Follow-up extends to 7 years now. The patient is at New York Heart Association functional class I, is very active, and has had no episodes of rejection and no evidence of recurrence. Echocardiograms reveal normal function, and control computed tomography and liver and bone scans results have been entirely normal. On no occasion and in accumulation with the standard immunosuppression, was any type of extra chemotherapy given to this patient. metastases at distant locations in the body [5] are not found by computed tomography or perfusion scans. Transplantation might be an alternative, but due to immunosuppression, there is always the risk of tumor recurrence or de novo malignancies related to chronic use of immunosuppressant agents; for example, lymphoma has an incidence of 2.3% to 13% in transplant recipients [ 1, 5, 6 ].
Another issue is long-term survival after transplantation for cardiac malignancies. In a series of 21 patients with nonresectable cardiac tumors for whom transplantation was offered, mean survival was 12 months, and only 7 patients survived a mean of 29 months free of recurrence [5] . Despite these poor results, transplantation remains the only option for selected patients with nonresectable tumors but localized disease [5] . Adjuvant chemotherapy or radiotherapy, or both, do not seem to improve survival and are not useful [1, 5] and were not used in our patient.
In favor of transplantation for our patient, we had a nonresectable, recurring tumor in a young patient and the disease was strictly localized to the heart. Against transplantation was the history of previous lymphoma (eventually predisposing to de novo lymphoma induced by malignancy immunosuppression) and the poor results usually obtained with this treatment for this type of patients, although case series are very limited. Mean survival for patients with cardiac sarcoma has been established between 9 and 11 months [1] . Our patient has been monitored for 7 years until now, without evidence of recurrence of any type and without cardiac rejection, which certainly is an unusually good result.
Cardiac transplantation must be considered a valid therapeutic option for selected patients with nonresectable cardiac sarcomas without evidence of distant metastatic disease. Intermediate-term or even long-time survival can sometimes be achieved.
